Vaccine for prophylaxis of differential and columbia adsorbated, collected acellular, polyomielitis inactivated, infections caused by haemophilus
influenzae type b concentrated, total: 6470640.
Pipeline Products for Haemophilus
influenzae Type B Infections - Overview 9
influenzae serotype a as a cause of serious invasive infections.
2002) examined the prevalence of Alloiococcus otitidis, Moraxella catarrhalis, Streptococcus pneumoniae and Haemophilus
influenza with the application of culture and Multiplex PCR methods.
Evaluating the immunogenicity and safety of Haemophilus
influenzae type-B conjugate vaccine (Hib) in stable COPD patients.
Primarly X and V factors were performed onto triptic soy agar (TSA) to exclude Haemophilus
Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus
The report provides comprehensive information on the therapeutics under development for Haemophilus
influenzae Type B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
licensed monovalent Haemophilus
b Conjugate Vaccine [Tetanus Toxoid Conjugate], manufactured by Sanofi Pasteur, Swiftwater, PA) was assessed 1 month after completion of the primary series (after dose 3) using anti-PRP antibody concentrations [greater than or equal to]0.
Conclusion: Based on these observations, it is hypothesized that some strains of nontypeable Haemophilus
influenzae infect some specific areas more than other parts.
It can be differentiated from other Haemophilus
This report provides comprehensive information on the therapeutic development for Haemophilus
Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Children that suffer from recurrent otitis media (ear infection) despite highly individualized treatment plans don't respond well to vaccines against certain strains of Streptococcus pneumonia and Haemophilus
The first update in almost 20 years to the Centers for Disease Control and Prevention's statement on Haemophilus
influenzae b will reflect changes in the epidemiology of the disease and the vaccines available to prevent it.
This report provides information on the therapeutic development for Haemophilus
Influenzae Type b Infections, complete with latest updates, and special features on late-stage and discontinued projects.